BioNTech lung cancer drug extends survival versus chemotherapy
Patients treated with gotistobart lived for a median 18.5 months, compared with 10 months for those given the standard-of-care chemotherapy.
We haven't written up this one. Japan Times has the full story — the link below goes straight to it.